Nexium (esomeprazole magnesium) manufactured by AstraZeneca is a proton pump inhibitor (PPI) approved by the U.S. Food and Drug Administration (FDA) in 2001 for the treatment of peptic ulcer disease, gastroesophageal reflux disease, dyspepsia, and Zollinger-Ellison syndrome. In late 2010, AstraZeneca announced a co-promotion agreement with Daiichi Sankyo to distribute Nexium.
The Journal of the American Medical Association (JAMA) published results of a study related to Nexium intake in their February 2016 issue stating that the risk of chronic kidney disease (CKD) increases by 20 to 50% in patients taking Nexium and similar products.
A 2009 study based in Copenhagen showed that PPI use may cause a rebound acid release if discontinued. This indicates that patients may become dependent on the medications.
In 2006, JAMA published a study which showed that long-term use of PPI medications may increase the risk of hip fractures in the elderly.
Since 2006, PPI medications including Nexium have been the subject of investigations related to harm.